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Levodopa-carbidopa-entacapone is a sin-
gle combination drug consisting of levo-
dopa (aromatic amino acid), carbidopa 
(dopa-decarboxylase inhibitor), and en-
tacapone (catechol-O-methyltransferase 
inhibitor). The Food and Drug Admin-
istration approved levodopa-carbidopa-
entacapone in 2003, as treatment for 
idiopathic Parkinson’s disease in patients 
experiencing signs and symptoms of wear-
ing-off. Although various adverse drug re-
actions of levodopa-carbidopa-entacapone 
have been recorded, there has been no re-
ported case of levodopa-carbidopa-entaca-
pone overdose. We report the first case of 
signs and symptoms of an overdose of lev-
odopa-carbidopa-entacapone (levodopa: 
3000 mg; carbidopa: 750 mg; entacapone: 
6000 mg) in a suicide attempt, presenting 
as altered mentality, xanthoderma, and 
yellowish sclera without hyperbilirubine-
mia.
Key words: levodopa-carbidopa-entaca-
pone, Parkinson’s disease, drug overdose, 
xanthoderma, yellowish sclera, toxicology
INTRODUCTION 
Levodopa-carbidopa-entacapone is a triple 
combination drug containing levodopa, 
carbidopa, and entacapone. In 2003, this 
drug was approved by the Food and Drug 
Administration (FDA) and considered 
the main treatment option for Parkinson’s 
disease (PD). (1) Adverse drug reactions 
associated with the recommended dose 
of levodopa-carbidopa-entacapone have 
been reported to be at least 3% greater 
than placebo incidences, and these include 
dyskinesia, urine discoloration, diarrhea, 
nausea, hyperkinesia, vomiting and dry 
mouth. (2) 
Concerning the overdose of this drug, a 
few cases of levodopa alone or levodopa-
carbidopa overdose have been reported. 
(3-6) However, there have been no reports 
on levodopa-carbidopa-entacapone over-
dose. We report the first case of a patient 
who ingested excess levodopa-carbidopa-
entacapone in an attempt to commit sui-
cide. 
CASE PRESENTATION
A 77-year-old woman presented at our 
emergency department, with complaint 
from her son of altered mental status. She 
had a previous medical history of PD, for 
which she had received treatment for 4 
years. In the morning, her son found her 
unconscious in the living room with 30 
torn and remnants of the tablet. The last 
call was to her son 30 minutes before. 
Upon arrival, her vital signs were unstable 
(60/40 mmHg-110 beats/min-26 breaths/
min-34°C) Physical examination showed 
the patient was in a state of stupor, with 
dilated pupils, sluggish light reflex, xan-
thoderma of the whole body (figure 1A) 
and yellowish sclera (figure 1B). Initial 
resuscitation included tracheal intuba-
tion, intravenous fluid infusions, inotropic 
agents, gastric lavage and orally adminis-
tered activated charcoal. At that point, we 
suspected a case of hyperbilirubinemia, re-
lated to hepatic failure due to ingestion of 
an unknown drug. 
The laboratory findings including liver 
function test (total bilirubin: 0.9 mg/dL; 
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Figure 1. Photograph images of the patients’ whole body (A), eye (B), and urine via Foley 
catheter (C). These show yellowish skin color (xanthoderma) (A) and yellowish sclera (B). 
Urine color is somewhat dark yellow to reddish (C). 
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direct bilirubin: 0.3 mg/dL; aspartate ami-
notransferase: 46 u/L; alanine aminotrans-
ferase: 3 u/L), creatinine kinase (161 U/L), 
lactate dehydrogenase (330 U/L), and 
renal function tests (urea: 18.4 mg/dL; 
creatinine: 0.78 g/dL; urine neutrophil 
gelatinase-associated lipocalin (NGAL): 
85 ng/mL) were within normal range. The 
results of urine toxicology screening were 
negative for benzodiazepine, tricyclic anti-
depressant, and barbiturate. Urine analysis 
showed no hematuria or pyuria, but her 
urine color was dark yellow to reddish (fig-
ure 1C). We performed brain computed 
tomography (CT), and an abdominal CT 
for evaluating the liver and kidney; how-
ever, there was no abnormal finding.
After initial resuscitation, her son brought 
along her remaining drug, which turned 
out to be a dose for the treatment of PD 
(single tablet: levodopa 100 mg+carbidopa 
25 mg+entacapone 200 mg). After mental 
recovery, she confessed that she had inten-
tionally taken an overdose of the drug for 
suicide. Thus, we diagnosed a levodopa-
carbidopa-entacapone overdose (levo-
dopa: 3000 mg; carbidopa: 750 mg; enta-
capone: 6000 mg). We can exclude effect 
of the rhabdomyolysis because creatinine 
kinase and lactate dehydrogenase were 
normal. She was admitted to the intensive 
care unit for further management. On hos-
pital day (HD)-3, she was extubated and 
recovered a normal skin, sclera, and urine 
color. On HD-10, she was discharged to 
a rehabilitation center for supportive care 
and rehabilitation. In order to exclude the 
effects of chronic levodopa-carbidopa-en-
tacapone use on skin color, the patient was 
followed up once a month for 6 months 
and was free from any adverse events for a 
total follow-up period.
DISCUSSION
Levodopa-carbidopa-entacapone is a sin-
gle combination tablet consisting of levo-
dopa (aromatic amino acid), carbidopa 
(dopa-decarboxylase inhibitor), and en-
tacapone (catechol-O-methyltransferase 
(COMT) inhibitor). (1) Until now, an over-
dose of levodopa alone (3) or that of levo-
dopa-carbidopa (4-6) has been reported 
(table 1). Based on previous reports, (3-6) 
the symptoms of altered mental status and 
hypotension in our patient may be related 
to levodopa since only levodopa could 
cross the blood-brain barrier freely, unlike 
carbidopa and entacapone. However, there 
was no report concerning the overdose of 
levodopa-carbidopa-entacapone. Especial-
ly, complications related to the overdose 
of entacapone have not been revealed, al-
though its adverse reactions have been 
investigated. Common adverse reactions 
of the recommended dose of entacapone 
are dyskinesia and urine discoloration. 
Among these, urine discoloration was ob-
served in our patient. This discoloration is 
due to the water-soluble metabolite of the 
entacapone (glucuronide conjugates). (2,7) 
However, the cause of the change in skin 
color (xanthoderma) is unclear because it 
has not been reported as an adverse reac-
tion of levodopa, carbidopa, and entaco-
pone in animal studies and post-marketing 
surveillance. We hypothesized three po-
tential etiological mechanisms related to 
skin color change. The first hypothesis was 
that hyperbilirubinemia, due to the hepatic 
impairment, may have resulted in jaun-
dice and icteric sclera, and the subsequent 
yellowish discoloration of the skin and 
sclera. The second hypothesis was that the 
stimulation of melanin production due to 
levodopa may have resulted in the change 
of the color of the skin. (8) The color of 
melanin is blue, dark blue, and black. (9) 
The third hypothesis was that high levels 
of the conjugated entacapone caused an 
accumulation of glucuronide conjugates 
in whole body tissues. Plasma entacapone 
Table 1. Reported studies of the drug overdosage in Parkinson’s disease patients with levodopa therapy




Symptoms Abnormal laboratory 
finding at the time of the 
hospital visit 
Interval between 
drug ingestion and 
hospital visit






 Altered mentality, dia-
phoretic.and restless,
constant speech, jerk 
movement
Elevated serum CK, 
LDH, creatinine, glutamic 
oxaloacetic acid, glutarnic 
pyruvic acid transaminase
Several hours
























Not reported About 1~2 hours











Elevated serum CK, aspar-
tate aminotransferase
2.5 hours












None 30 minutes~1 hour
CK, creatinine kinase; LDH, lactate dehydrogenase.
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level is dose-dependent; thus by ingesting 
an excess of the entacapone, the glucuro-
nide conjugates of the entacapone in the 
hepatocyte and the small intestine might 
increase. Although 90% of the glucuronide 
conjugate in the small intestine is excreted 
via feces, 10% remains in circulation. (2,8) 
As seen in discolorated urine, the color of 
the glucuronide conjugate is dark yellow to 
reddish. In our patient’s case, the skin and 
sclera color were yellowish, and liver func-
tion test including bilirubin was normal; 
thus, the third hypothesis provided a more 
likely explanation. 
The differential diagnosis between xantho-
derma with yellowish sclera related to the 
levodopa-carbidopa-entacapone overdose 
and jaundice with icteric sclera related to 
the hepatic impairment was important 
because the optimal treatment could be 
different. In the treatment of levodopa-
carbidopa-entacapone overdose, hemodi-
alysis is unlikely to be beneficial due to the 
high protein binding of the COMT inhibi-
tors. Patients are therefore started gradu-
ally on inotropic agents, since COMT 
inhibitors may interfere with the metabo-
lism of agents such as dopamine and nor-
epinephrine, thereby causing a prolonged 
response. (2) 
Our case underscores the importance of 
the knowledge for new adverse reactions, 
related to levodopa-carbidopa-entacapone 
overdose. For optimal management, emer-
gency physicians should keep in mind 
that an overdose of levodopa-carbidopa-
entacapone in PD patients may be accom-
panied by altered mentality, xanthoderma 
and yellowish sclera.
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